Abstract:Objective To analyze the correlation between protein expression of X -ray repair cross complementing group 1 (XRCC1)and excision repair cross complementing 1 (ERCC1)with efficacy of concurrent radiochemotherapy(CRT)and the prognosis of patients with esophageal aquamous cell carcinoma(ESCC).Methods Immunohistochemical SP method was used to measure the protein expression of XRCC1 and ERCC in 98 ESCC tissue samples before CRT.The Kaplan -Meier method was used for survival analysis,and the log rank test was used for analyzing the survival difference between negative and positive sam-ples.The Cox model was used for multivariate prognostic analysis.Results XRCC1 and ERCC1 protein were mainly expressed in the nucleus in ESCC.There was no correlation between them (r =-0.024,P =0.811 ).The positive expression rate of XRCC1 protein in ESCC tissues and normal esophageal tissues were 57.1%(56 /98)and 13.3%(4 /30)respectively (χ2 =17.702,P =0.000).The positive expression rate of ERCC1 protein in ESCC tissues and normal esophageal tissues were 36.7%(36 /98)and 10%(3 /30)respectively(χ2 =7.749,P =0.006).The level of ERCC1 was not correlated with clinical pathologic characteristics (P >0.05).The positive expression rate of ERCC1 protein in negative lymphnode group was 44.9% (31 /69), higher than 17.2% (5 /29)in positive lymphnode group,and the difference was statistically significant (χ2 =8.183,P =0.004).The patients with positive XRCC1 expression and negative XRCC1 expression had similar short -term responses(χ2 =0.894,P =0.344)as well as similar survival rates(χ2 =0.266,P =0.606).The RR of ERCC1 negative expression group was 90.3%(56 /62),and the RR of ERCC1 positive expression group was 80.5%(29 /36),but there was no statistically significant difference (χ2 =1.888,P =0.169).The median overall survival periods of ERCC1 negative expression group was 39 months (95% CI:29.313 ~48.687 months),higher than 25 months (95% CI:18.559 ~31.441 months)in positive expression group, the difference was statistically significant (χ2 =10.174,P =0.001).In multivariate analysis,the expression of ERCC1 was closely correlated with overall survival and was the independent prognostic factor (P =0.010,95% CI:1.180 ~3.450).Conclusion ERCC1 expression was associated with the efficacy of CRT,and the patients with ERCC1 positive expression had poor prognosis.

Elevated Expression of Rad51 is Correlated with Decreased Survival in Resectable Esophageal Squamous Cell Carcinoma.

Rad51 and Systemic Inflammatory Indicators as Novel Prognostic Markers in Esophageal Squamous Cell Carcinoma

Analysis of correlation between protein expression of XRCC1 and ERCC1 with efficacy of concurrent radiochemotherapy and the prognosis of patients with esophageal aquamous cell carcinoma

Expression of RAD51 and Its Clinical Impact in Oral Squamous Cell Carcinoma.

The clinical significance of p53 and pRb signal pathway in esophageal cancer patients

Clinical Role of Excision Repair Cross-Complementing 1 Gene Expression in Resected Esophageal Squamous Cell Carcinoma: A Meta-Analysis

The clinical significance of ERCC1 in predicting the response to platinum-based chemoradiotherapy and prognosis of esophageal squamous cell carcinoma

Association of decreased expression of long non-coding RNA LOC285194 with chemoradiotherapy resistance and poor prognosis in esophageal squamous cell carcinoma

High-Level Expression of Rad51 is an Independent Prognostic Marker of Survival in Non-Small-Cell Lung Cancer Patients

Association of RASSF 1 expression with radiosensitivity / prognosis in esophageal squamous cell carcinoma

Overexpression of Rad51 Predicts Poor Prognosis in Colorectal Cancer: Our Experience with 54 Patients

Prognostic Relevance of Id-1 Expression in Patients with Resectable Esophageal Squamous Cell Carcinoma

Prognostic and predictive role of COX-2, XRCC1 and RASSF1 expression in patients with esophageal squamous cell carcinoma receiving radiotherapy.

High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy

High Expression of Rad51c Predicts Poor Prognostic Outcome and Induces Cell Resistance to Cisplatin and Radiation in Non-Small Cell Lung Cancer

High Expression of P300 Has an Unfavorable Impact on Survival in Resectable Esophageal Squamous Cell Carcinoma.

RAD51 is a poor prognostic marker and a potential therapeutic target for oral squamous cell carcinoma

Elevated P53 Expression Levels Correlate with Tumor Progression and Poor Prognosis in Patients Exhibiting Esophageal Squamous Cell Carcinoma.

[Expression and Clinical Significance of BRCA1 in Human Esophageal Squamous Cell Carcinoma].

Reduced EBP50 Expression or Mis-Localization of the EBP50 Protein is Associated with the Malignant Progression of Esophageal Squamous Cell Carcinoma.

Systematical identification of key genes and regulatory genetic variants associated with prognosis of esophageal squamous cell carcinoma